1
|
Arca-Lafuente S, Martínez-Román P, Mate-Cano I, Madrid R, Briz V. Nanotechnology: A reality for diagnosis of HCV infectious disease. J Infect 2019; 80:8-15. [PMID: 31580870 DOI: 10.1016/j.jinf.2019.09.010] [Citation(s) in RCA: 16] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/09/2019] [Accepted: 09/26/2019] [Indexed: 01/24/2023]
Abstract
Hepatitis C virus (HCV) is the primary etiologic agent of liver cirrhosis or hepatocellular carcinoma. HCV elevated infection rates are mostly due to the lack of an accurate and accessible screening and diagnosis, especially in low- and middle-income countries. Conventional HCV diagnostic algorithm consists of a serological test followed by a nucleic acid test. This sequence of tests is time consuming and not affordable for low-resource settings. Nanotechnology have introduced new promising tests for the diagnose of infectious diseases. Based on the employment of nanoparticles and other nanomaterials which lead to highly sensitive and specific nanoscale tests, most of them target pathogen genome. Implementation of nanoscale tests, which are affordable, portable and easy to use by non-specialized personal, would improve HCV diagnosis algorithm. In this review, we have summed up the current emerging nanotechnology tools, which will improve actual screening and treatment programs, and help to reach HCV elimination proposal.
Collapse
Affiliation(s)
- Sonia Arca-Lafuente
- Laboratory of Reference and Research on Viral Hepatitis, National Center for Microbiology, Institute of Health Carlos III, Majadahonda, Madrid, Spain; BioAssays SL, c/Faraday, 7, Parque Científico de Madrid, Campus de Cantoblanco, 28049 Madrid, Spain
| | - Paula Martínez-Román
- Laboratory of Reference and Research on Viral Hepatitis, National Center for Microbiology, Institute of Health Carlos III, Majadahonda, Madrid, Spain
| | - Irene Mate-Cano
- Laboratory of Reference and Research on Viral Hepatitis, National Center for Microbiology, Institute of Health Carlos III, Majadahonda, Madrid, Spain
| | - Ricardo Madrid
- BioAssays SL, c/Faraday, 7, Parque Científico de Madrid, Campus de Cantoblanco, 28049 Madrid, Spain.
| | - Verónica Briz
- Laboratory of Reference and Research on Viral Hepatitis, National Center for Microbiology, Institute of Health Carlos III, Majadahonda, Madrid, Spain.
| |
Collapse
|
2
|
Bilan R, Ametzazurra A, Brazhnik K, Escorza S, Fernández D, Uríbarri M, Nabiev I, Sukhanova A. Quantum-dot-based suspension microarray for multiplex detection of lung cancer markers: preclinical validation and comparison with the Luminex xMAP ® system. Sci Rep 2017; 7:44668. [PMID: 28300171 PMCID: PMC5353738 DOI: 10.1038/srep44668] [Citation(s) in RCA: 35] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/14/2016] [Accepted: 02/13/2017] [Indexed: 11/21/2022] Open
Abstract
A novel suspension multiplex immunoassay for the simultaneous specific detection of lung cancer markers in bronchoalveolar lavage fluid (BALF) clinical samples based on fluorescent microspheres having different size and spectrally encoded with quantum dots (QDEM) was developed. The designed suspension immunoassay was validated for the quantitative detection of three lung cancer markers in BALF samples from 42 lung cancer patients and 10 control subjects. Tumor markers were detected through simultaneous formation of specific immune complexes consisting of a capture molecule, the target antigen, and biotinylated recognition molecule on the surface of the different QDEM in a mixture. The immune complexes were visualized by fluorescently labeled streptavidin and simultaneously analyzed using a flow cytometer. Preclinical validation of the immunoassay was performed and results were compared with those obtained using an alternative 3-plex immunoassay based on Luminex xMAP® technology, developed on classical organic fluorophores. The comparison showed that the QDEM and xMAP® assays yielded almost identical results, with clear discrimination between control and clinical samples. Thus, developed QDEM technology can become a good alternative to xMAP® assays permitting analysis of multiple protein biomarkers using conventional flow cytometers.
Collapse
Affiliation(s)
- Regina Bilan
- Laboratory of Nano-Bioengineering, National Research Nuclear University MEPhI (Moscow Engineering Physics Institute), 115409 Moscow, Russian Federation
| | - Amagoia Ametzazurra
- Department of Research and Development, Progenika Biopharma S.A., Derio, 48160 Spain
| | - Kristina Brazhnik
- Laboratory of Nano-Bioengineering, National Research Nuclear University MEPhI (Moscow Engineering Physics Institute), 115409 Moscow, Russian Federation
| | - Sergio Escorza
- Department of Research and Development, Progenika Biopharma S.A., Derio, 48160 Spain
| | - David Fernández
- Department of Research and Development, Progenika Biopharma S.A., Derio, 48160 Spain
| | - María Uríbarri
- Department of Research and Development, Progenika Biopharma S.A., Derio, 48160 Spain
| | - Igor Nabiev
- Laboratory of Nano-Bioengineering, National Research Nuclear University MEPhI (Moscow Engineering Physics Institute), 115409 Moscow, Russian Federation.,Laboratoire de Recherche en Nanosciences, LRN - EA4682, Université de Reims Champagne-Ardenne, 51096 Reims, France
| | - Alyona Sukhanova
- Laboratory of Nano-Bioengineering, National Research Nuclear University MEPhI (Moscow Engineering Physics Institute), 115409 Moscow, Russian Federation.,Laboratoire de Recherche en Nanosciences, LRN - EA4682, Université de Reims Champagne-Ardenne, 51096 Reims, France
| |
Collapse
|
3
|
Qiu P, Stevens R, Wei B, Lahser F, Howe AYM, Klappenbach JA, Marton MJ. HCV genotyping from NGS short reads and its application in genotype detection from HCV mixed infected plasma. PLoS One 2015; 10:e0122082. [PMID: 25830316 PMCID: PMC4382110 DOI: 10.1371/journal.pone.0122082] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/15/2014] [Accepted: 02/10/2015] [Indexed: 12/12/2022] Open
Abstract
Genotyping of hepatitis C virus (HCV) plays an important role in the treatment of HCV. As new genotype-specific treatment options become available, it has become increasingly important to have accurate HCV genotype and subtype information to ensure that the most appropriate treatment regimen is selected. Most current genotyping methods are unable to detect mixed genotypes from two or more HCV infections. Next generation sequencing (NGS) allows for rapid and low cost mass sequencing of viral genomes and provides an opportunity to probe the viral population from a single host. In this paper, the possibility of using short NGS reads for direct HCV genotyping without genome assembly was evaluated. We surveyed the publicly-available genetic content of three HCV drug target regions (NS3, NS5A, NS5B) in terms of whether these genes contained genotype-specific regions that could predict genotype. Six genotypes and 38 subtypes were included in this study. An automated phylogenetic analysis based HCV genotyping method was implemented and used to assess different HCV target gene regions. Candidate regions of 250-bp each were found for all three genes that have enough genetic information to predict HCV genotypes/subtypes. Validation using public datasets shows 100% genotyping accuracy. To test whether these 250-bp regions were sufficient to identify mixed genotypes, we developed a random primer-based method to sequence HCV plasma samples containing mixtures of two HCV genotypes in different ratios. We were able to determine the genotypes without ambiguity and to quantify the ratio of the abundances of the mixed genotypes in the samples. These data provide a proof-of-concept that this random primed, NGS-based short-read genotyping approach does not need prior information about the viral population and is capable of detecting mixed viral infection.
Collapse
Affiliation(s)
- Ping Qiu
- Molecular Biomarker and Diagnostics, Merck Research Laboratories, Rahway, New Jersey, United States of America
- * E-mail:
| | - Richard Stevens
- Target & Pathway Biology, Merck Research Laboratories, Boston, Massachusetts, United States of America
| | - Bo Wei
- Molecular Biomarker and Diagnostics, Merck Research Laboratories, Rahway, New Jersey, United States of America
| | - Fred Lahser
- Infectious Diseases and Clinical Virology, Merck Research Laboratories, Kenilworth, New Jersey, United States of America
| | - Anita Y. M. Howe
- Infectious Diseases and Clinical Virology, Merck Research Laboratories, Kenilworth, New Jersey, United States of America
| | - Joel A. Klappenbach
- Target & Pathway Biology, Merck Research Laboratories, Boston, Massachusetts, United States of America
| | - Matthew J. Marton
- Molecular Biomarker and Diagnostics, Merck Research Laboratories, Rahway, New Jersey, United States of America
| |
Collapse
|